Stoke Therapeutics, Inc. $STOK Shares Purchased by Janus Henderson Group PLC

Posted by Geri Gentry on Aug 2nd, 2026

Janus Henderson Group PLC boosted its stake in Stoke Therapeutics, Inc. (NASDAQ:STOK – Free Report) by 11.2% during the first quarter, Holdings Channel.com reports. The institutional investor owned 1,612,781 shares of the company’s stock after acquiring an additional 161,848 shares during the period. Janus Henderson Group PLC’s holdings in Stoke Therapeutics were worth $52,456,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. AQR Capital Management LLC raised its holdings in shares of Stoke Therapeutics by 1.2% in the fourth quarter. AQR Capital Management LLC now owns 29,467 shares of the company’s stock worth $935,000 after acquiring an additional 354 shares during the last quarter. Strs Ohio grew its holdings in shares of Stoke Therapeutics by 9.4% during the fourth quarter. Strs Ohio now owns 7,000 shares of the company’s stock worth $222,000 after buying an additional 600 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Stoke Therapeutics by 31.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,776 shares of the company’s stock worth $88,000 after acquiring an additional 658 shares during the last quarter. Generali Investments Management Co LLC grew its stake in Stoke Therapeutics by 41.0% in the 4th quarter. Generali Investments Management Co LLC now owns 2,471 shares of the company’s stock worth $78,000 after acquiring an additional 718 shares during the period. Finally, First Trust Advisors LP raised its holdings in Stoke Therapeutics by 0.5% in the 1st quarter. First Trust Advisors LP now owns 163,459 shares of the company’s stock valued at $5,322,000 after acquiring an additional 780 shares during the last quarter.

Stoke Therapeutics Stock Down 3.9%

STOK stock opened at $28.86 on Friday. The company has a market cap of $1.80 billion, a price-to-earnings ratio of -10.27 and a beta of 1.17. The business has a fifty day simple moving average of $30.38 and a 200-day simple moving average of $31.99. Stoke Therapeutics, Inc. has a 52 week low of $12.40 and a 52 week high of $40.22.

Stoke Therapeutics (NASDAQ:STOK – Get Free Report) last issued its earnings results on Thursday, May 7th. The company reported ($0.79) earnings per share for the quarter, topping the consensus estimate of ($0.80) by $0.01. Stoke Therapeutics had a negative return on equity of 48.84% and a negative net margin of 529.20%.The business had revenue of $6.23 million for the quarter, compared to analyst estimates of $6.48 million. As a group, analysts expect that Stoke Therapeutics, Inc. will post -3.22 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Barry Ticho sold 1,795 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $30.58, for a total value of $54,891.10. Following the transaction, the insider directly owned 34,826 shares in the company, valued at $1,064,979.08. This trade represents a 4.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, General Counsel Jonathan Allan sold 1,457 shares of Stoke Therapeutics stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $29.95, for a total value of $43,637.15. Following the completion of the transaction, the general counsel directly owned 18,086 shares in the company, valued at $541,675.70. This represents a 7.46% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 9.60% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on STOK. The Goldman Sachs Group started coverage on Stoke Therapeutics in a report on Monday, July 13th. They set a “buy” rating and a $44.00 price objective on the stock. Weiss Ratings lowered Stoke Therapeutics from a “hold (c)” rating to a “sell (d)” rating in a research note on Monday, May 11th. Finally, BTIG Research reissued a “buy” rating and issued a $39.00 price target on shares of Stoke Therapeutics in a research note on Monday, May 11th. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Stoke Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $43.00.

Read Our Latest Report on STOK

About Stoke Therapeutics

(Free Report)

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.